Incidence of adequate and inadequate therapies in patients with an implantable Cardioverter Defibrillator for primary prevention

被引:0
|
作者
Kreuz, J. [1 ]
Balta, O. [1 ]
Liliegren, N. [3 ]
Ezmailzadeh, B. [2 ]
Schneider, C. [2 ]
Welz, A. [2 ]
Nickenig, G. [1 ]
Schwab, J. O. [1 ]
机构
[1] Univ Klin Bonn, Med Klin & Poliklin 2, Sigmund Freud Str 25, D-53105 Bonn, Germany
[2] Univ Klin Bonn, Klin & Poliklin Herzchirurg, Bonn, Germany
[3] Medtronic Inc, Dusseldorf, Germany
来源
关键词
sudden cardiac death; ICD; VT; primary prevention;
D O I
10.1007/s00398-007-0559-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We evaluated the number of adequate and inappropriate therapies for ventricular tachyarrhythmia and trigger mechanisms in 55 MADIT II (MII) and 86 SCD-HeFT (SH) like patients. Results 399 adequate episodes could be analysed from 31 patients implanted according to the MII trial, while 502 adequate episodes were registered in 47 patients matching the SIT inclusion criteria (mean follow-up in both collectives 33 +/- 19 months). The results of the present study regarding inappropriate therapies illustrate that patients from the MII cohort had 39 inadequately treated episodes (9% of all included episodes). Patients from the SH group were treated inadequately 76 times (15% of all included episodes). 18% of the MII group (10 patients) and even 22% of the SH collective (19 patients) were treated inadequately at least once. Discussion Our data of > 500 malignant ventricular arrhythmias substantiate the use of an ICD in a collective of primary prevention patients. Therefore, the findings of our study encourage the need of an ICD in these patients. On the other hand, despite skilled ICD programming and an optimal medical treatment, a relevant rate of inadequate therapies could be demonstrated. Conclusion Although a noteworthy proportion of inadequate ICD interventions was observed, our study supports the indication of an ICD implant in a collective of patients who are in danger of sudden cardiac death.
引用
收藏
页码:8 / 12
页数:5
相关论文
共 50 条
  • [31] Incidence of and predictors for appropriate implantable cardioverter-defibrillator therapy in patients with a secondary preventive implantable cardioverter-defibrillator indication
    Schaer, Beat
    Kuehne, Michael
    Reichlin, Tobias
    Osswald, Stefan
    Sticherling, Christian
    EUROPACE, 2016, 18 (02): : 227 - 231
  • [32] Implantable Cardioverter-Defibrillator Underutilization in Primay Prevention Patients
    Ennis, Cynthia
    McGuiness, Matthew
    Vohora, Rishi
    Ennis, Stephanie
    Rosenthal, Lawrence
    CIRCULATION, 2008, 118 (18) : S1464 - S1464
  • [33] Dutch Outcome in Implantable Cardioverter-Defibrillator Therapy: Implantable Cardioverter-Defibrillator-Related Complications in a Contemporary Primary Prevention Cohort
    van Barreveld, Marit
    Verstraelen, Tom E.
    van Dessel, Pascal F. H. M.
    Boersma, Lucas V. A.
    Delnoy, Peter Paul H. M.
    Tuinenburg, Anton E.
    Theuns, Dominic A. M. J.
    van der Voort, Pepijn H.
    Kimman, Geert-Jan
    Buskens, Erik
    Zwinderman, Aeilko H.
    Wilde, Arthur A. M.
    Dijkgraaf, Marcel G. W.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2021, 10 (07):
  • [34] Workforce affiliation in primary and secondary prevention implantable cardioverter defibrillator patients: a nationwide Danish study
    Rosenkranz, Simone H.
    Wichmand, Charlotte H.
    Smedegaard, Laerke
    Moller, Sidsel
    Bjerre, Jenny
    Schou, Morten
    Torp-Pedersen, Christian
    Philbert, Berit T.
    Larroude, Charlotte
    Melchior, Thomas M.
    Nielsen, Jens C.
    Johansen, Jens B.
    Riahi, Sam
    Holmberg, Teresa
    Gislason, Gunnar
    Ruwald, Anne-Christine
    EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES, 2023, 10 (04) : 314 - 325
  • [35] The follow-up of patients with chronic heart failure and implantable cardioverter defibrillator in primary prevention
    Kerekanic, Michal
    Misikova, S.
    Komanova, E.
    Sedlak, J.
    Farkas, J.
    Stancak, B.
    EUROPEAN JOURNAL OF HEART FAILURE, 2019, 21 : 38 - 39
  • [36] Implantable cardioverter-defibrillator therapies are associated with increased incidence of depression and mortality reply
    Pushkarev, Georgiy S.
    Kuznetsov, Vadim A.
    Fisher, Yakov A.
    Soldatova, Anna M.
    Enina, Tatiana N.
    TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, 2018, 46 (08): : 742 - 743
  • [37] Atrial fibrillation predicts appropriate shocks in primary prevention implantable cardioverter-defibrillator patients
    Smit, Marcelle D.
    Van Dessel, Pascal F. H. M.
    Rienstra, Michiel
    Nieuwland, Wybe
    Wiesfeld, Ans C. P.
    Tan, Eng S.
    Anthonio, Rutger L.
    Van Veldhuisen, Dirk J.
    Van Gelder, Isabelle C.
    EUROPACE, 2006, 8 (08): : 566 - 572
  • [38] IS THERE A GENDER DISPARITY IN PATIENTS WITH SYSTOLIC HEART FAILURE RECEIVING AN IMPLANTABLE CARDIOVERTER DEFIBRILLATOR FOR PRIMARY PREVENTION?
    Nahass, Meghan
    Hiltner, Emily
    Srivastava, Shreya
    Kassotis, John
    Sethi, Ankur
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (09) : 181 - 181
  • [39] The implantable cardioverter defibrillator in congestive heart failure patients in primary prevention: assessment of neuropsychological impact
    Garnero, S.
    Pomero, A.
    Vallauri, P.
    Leto, L.
    Testa, M.
    Feola, M.
    MINERVA CARDIOANGIOLOGICA, 2014, 62 (04): : 321 - 326
  • [40] Implantable Cardioverter Defibrillator for Primary Prevention in Patients with Severe Ventricular Dysfunction Awaiting Heart Transplantation
    Cantero-Perez, E. M.
    Sobrino-Marquez, J. M.
    Grande-Trillo, A.
    Lage-Galle, E.
    Rangel-Sousa, D.
    Esteve-Ruiz, I. M.
    Martinez-Martinez, A.
    TRANSPLANTATION PROCEEDINGS, 2013, 45 (10) : 3659 - 3661